Recent 8-K filings for SEPN

• May 11, 2026, 4:05 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631

  Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.

• April 13, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Septerna dosed first participants in Phase 1 trial of SEP-479 oral PTH1R agonist for hypoparathyroidism

  Phase 1 SAD/MAD trial evaluating safety, tolerability, PK/PD in up to 150 healthy volunteers.

• March 9, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Septerna posts Q4 net loss $10.7M, highlights positive Phase 1 data for SEP-631

  Phase 1 data: SEP-631 well-tolerated, once-daily oral dosing, complete wheal inhibition at 10 mg; Phase 2b in CSU planned H2 2026.

• March 2, 2026, 6:59 PM ET other material materiality 0.90 positive item 7.01item 8.01item 9.01

  Septerna reports positive Phase 1 data for oral MRGPRX2 NAM SEP-631, plans Phase 2 in chronic spontaneous urticaria

  SEP-631 well-tolerated; adverse event profile comparable to placebo across all doses studied

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected

  Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.

• August 11, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Septerna Q2 net loss $24.8M; cash $379.2M; Novo Nordisk upfront $195M extends runway into 2029

  Net loss of $24.8M for Q2 2025, up from $16.4M in Q2 2024; R&D expenses $22.2M, G&A $6.9M.

• July 2, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Septerna and Novo Nordisk collaboration becomes effective after HSR clearance

  Collaboration and License Agreement with Novo Nordisk became effective July 1, 2025.

• May 15, 2025, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  Septerna reports Q1 net loss $21.5M, $398.2M cash; Novo Nordisk deal up to $2.2B

  Collaboration with Novo Nordisk for oral small molecules in metabolic diseases: >$200M upfront and near-term, up to $2.2B total milestones plus royalties.

• May 14, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 7.01item 9.01

  Septerna & Novo Nordisk partner on oral small molecule obesity drugs; upfront $195M, potential $2.2B

  Collaboration covers up to 5 GPCR targets (GLP-1, GIP, glucagon) for oral small molecule therapies for obesity/T2D.

• March 27, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Septerna reports FY2024 net loss of $71.8M, discontinues SEP-786 Phase 1 trial

  Discontinued SEP-786 Phase 1 trial after two Grade 3 elevated unconjugated bilirubin events, reversible without liver injury.

• February 18, 2025, 6:59 PM ET other material materiality 0.85 negative item 7.01item 9.01

  Septerna discontinues SEP-786 Phase 1 trial after bilirubin events; plans next-gen PTH1R agonist

  Discontinued SEP-786 Phase 1 trial due to two Grade 3 unconjugated bilirubin events without ALT/AST elevation; no SAEs or liver injury.

• November 20, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO

  Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.55 · Most common event earnings

10 positive 2 negative 12 neutral

source · SEPN on sec.gov